Printer Friendly

IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS

 IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO
 COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
 CAMBRIDGE, Mass., Nov. 20 /PRNewswire/ -- ImmuLogic Pharmaceutical Corporation (NASDAQ: IMUL) announced today that it has signed a preliminary agreement with Marion Merrell Dow (NYSE: MKC) for the joint worldwide development and commercialization of ImmuLogic's ALLERVAX(tm) family of allergy therapeutics. The collaborative agreement includes an equity investment in ImmuLogic by Marion Merrell Dow as well as license and milestone payments.
 Under the collaborative agreement, ImmuLogic will have responsibility for development and manufacturing of the ALLERVAX products in the United States. The products will be jointly marketed in the U.S. by ImmuLogic and Marion Merrell Dow. Outside of the U.S., Marion Merrell Dow will have responsibility for development and marketing. The collaboration will be overseen by a committee that consists of an equal number of senior managers from ImmuLogic and Marion Merrell Dow.
 "This collaboration pairs ImmuLogic's expertise in immunology, peptide chemistry and molecular biology with the resouces and experience of the leader in the allergy market today," siad Richard E. Bagley, president and CEO of ImmuLogic. "We believe that the ALLERVAX products emerging from ImmuLogic's discoveries have significant potential to provide substantial improvements over existing allergy therapies. Our partnership with Marion Merrell Dow will greatly enhance our efforts to get these therapies to the patients who need them."
 Fred W. Lyons, Jr., president of Marion Merrell Dow, commented, "ImmuLogic's ALLERVAX product line represents a major opportunity for Marion Merrell Dow to expand its portfolio of innovative products to treat allergies. This collaborative agreement is in line with our long-standing commitment to the allergy/respiratory disease field and to our program of investing in the most promising new technolgies for pharmaceutical discovery."
 Malcolm L. Gefter, founder and chairman of the board of ImmuLogic, further commented that, "The agreement represents a major step in our growth as a company, allowing ImmuLogic to expand its capabilities in biopharmaceutical development, manufacturing and ultimately marketing. We are also pleased that Marion Merrell Dow will participate in ImmuLogic's growth through an equity purchase in the company."
 Under a stock purchase agreement signed today, Marion Merrell Dow will purchase 1 million shares of ImmuLogic common stock at a price of $18.00 per share, effective on completion of review by the Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act. For additional consideration, ImmuLogic has also granted Marion Merrell Dow an option to purchase 250,000 shares of ImmuLogic common stock.
 In addition, upon execution of a final collaboration agreement in early 1992, ImmuLogic will receive a $7 million license payment from Marion Merrell Dow. The agreement also provides for additional license fees and milestone payments, which could total an additional $25-35 million over the development period.
 ImmuLogic's ALLERVAX products are designed to treat allergies by addressing the underlying cause of the disorder, an inappropriate immune response to a foreign protein. The most advanced ALLERVAX product, CATVAX(tm) for the treatment of cat allergies, is currently in the preclinical development phase. This product is expected to enter clinical trials in early 1992. ImmuLogic is also developing ALLERVAX products to treat allergies to ragweed, dust mite, and grasses. Allergies affect over 20 percent of the world's population and the company estimates that approximatley 10 million Americans with allergies seek treatment in a doctor's office each year.
 Founded in 1987, ImmuLogic's technical approach is based upon an understanding of the molecular events controlling the human immune system. In addition to its allergy program, the company is collaborating with Merck & Co. to develop treatments for Type I diabetes and rheumatoid arthritis.
 Headquartered in Kansas City, Mo. Marion Merrell Dow is involved in the discovery, development, manufacturing and marketing of prescription and over-the-counter pharmaceutical products in North America, Europe and the Pacific Basin. Among Marion Merrell Dow's key prescription products are Seldane(tm), the world's top selling non-sedating antihistamine, and Seldane-D(tm) which combines Seldane(tm) with a leading decongestant.
 -0- 11/20/91
 /CONTACT: Janet C. Bush, vice president, finance and administration of ImmuLogic Pharmaceutical, 617-494-0060; Richard M. Johnson or Marion Merrell Dow, 816-966-4000/
 (IMUL MKC) CO: ImmuLogic Pharmaceutical Corporation; Marion Merrell Dow ST: Massachusetts; Missouri IN: MTC SU:


KM-PB -- NE013 -- 5516 11/20/91 15:07 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 20, 1991
Words:704
Previous Article:CMS ENERGY UNIT REPORTS RESULTS OF WELL PRODUCTION TESTING IN NEW GUINEA
Next Article:DEPARTMENT OF CONSUMER AFFAIRS ADVISES CAUTION BY THOSE DAMAGED BY THE OAKLAND HILLS FIRE
Topics:


Related Articles
ALTEON AND MARION MERRELL DOW EXPAND COLLABORATION ON DRUGS FOR DIABETES AND AGING
IMMULOGIC AND MARION MERRELL DOW SIGN FINAL ALLERVAX PRODUCT COMMERCIALIZATION AGREEMENT
SCIOS INC. AND MARION MERRELL DOW SIGN MAJOR RESEARCH AND DEVELOPMENT AGREEMENT TO DEVELOP NEW THERAPIES FOR ALZHEIMER'S DISEASE
MARION MERRELL DOW COMMITS TO MAJOR EXPANSION OF AFFYMAX ALLIANCE
MARION MERRELL DOW INC. AND MITSUBISHI KASEI CORP. ANNOUNCE NORTH AMERICAN COLLABORATION
MARION MERRELL DOW IN-LICENSES TWO DRUGS IN LATE-STAGE TRIALS FROM MERCK & CO.
ONCOGENE SCIENCE, INC. AND MARION MERRELL DOW COLLABORATIVE PROGRAM ADVANCES
MARION MERRELL DOW INC. TO CO-PROMOTE PRILOSEC(R) WITH ASTRA MERCK INC. IN THE UNITED STATES
MARION MERRELL DOW AND TEVA TO COLLABORATE ON MARKETING OF MULTIPLE SCLEROSIS TREATMENT
Chesapeake Biological Laboratories, Inc. Announces Manufacturing Collaboration With ImmuLogic Pharmaceutical Corporation

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters